Drug reference
Acute myelogenous leukaemia | Acute lymphocytic leukaemia ▶BY INTRAVENOUS INFUSION ▶Adult: (consult local protocol) Advanced AIDS-related Kaposi’s sarcoma (liposomal formulation only) ▶BY INTRAVENOUS INFUSION ▶Adult: (consult product literature)
PDF page 972
Myocardial insufficiency. previous treatment with maximum cumulative doses of daunorubicin or other anthracycline. recent myocardial infarction. severe arrhythmia
PDF page 972
Caution in handling—irritant to tissues
PDF page 972
Daunorubicin is available as conventional and liposomal formulations. These different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable.
PDF page 973
→Appendix 1: anthracyclines
PDF page 972
Abdominal pain. alopecia. amenorrhoea. anaemia. arrhythmias. ascites. atrioventricular block. azoospermia. bone marrow disorders. cardiac inflammation. cardiomyopathy. chills. congestive heart failure. cyanosis. death. dehydration. diarrhoea. dyspnoea. extravasation necrosis. fever. flushing. gastrointestinal disorders. haemorrhage. hepatomegaly. hyperpyrexia. hyperuricaemia. hypoxia. infection. ischaemic heart disease. leucopenia. mucositis. myocardial infarction. nail discolouration. nausea. nephropathy. neutropenia. oedema. pain. paraesthesia. pleural effusion. radiation injuries. shock. skin reactions. stomatitis. thrombocytopenia. thrombophlebitis. urine red. venous sclerosis. vomiting SIDE-EFFECTS, FURTHER INFORMATION Cardiotoxicity is cumulative and may be irreversible, however responds to treatment if detected early.
PDF pages 972, 973
Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 973
Avoid (teratogenic and carcinogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 973
Discontinue breast-feeding.
PDF page 973
For solution for infusion manufacturer advises caution. For powder for solution for infusion manufacturer advises caution in mild to moderate impairment; avoid in severe impairment. Dose adjustments Manufacturer advises dose reduction according to serum bilirubin concentration—consult product literature.
PDF page 973
Avoid in severe impairment. Dose adjustments Reduce dose by 25% if serum creatinine 105–265 micromol/litre. Reduce dose by 50% if serum creatinine greater than 265 micromol/litre.
PDF page 973
Cardiac monitoring essential.
PDF page 973
There can be variation in the licensing of different medicines containing the same drug. Solution for infusion ▶DaunoXome (Galen Ltd) Daunorubicin (as Daunorubicin hydrochloride citrate liposomal pegylated) 2 mg per 1 ml DaunoXome 50mg/25ml concentrate for solution for infusion vials | 1 vial P £250.00 Powder for solution for infusion ▶Daunorubicin (Non-proprietary) Daunorubicin (as Daunorubicin hydrochloride) 20 mg Daunorubicin 20mg powder for solution for infusion vials | 10 vial P £715.00 (Hospital only)
PDF page 973
(consult local protocol)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 972
(consult product literature)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 972
